Trial Profile

An Exploratory Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of HLX07 (Recombinant Anti-EGFR Humanized Monoclonal Antibody) Combined With Chemotherapy in Patients With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 07 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pimurutamab (Primary) ; Carboplatin; Cisplatin; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Paclitaxel
Indications Solid tumours
Focus Adverse reactions
Sponsors Shanghai Henlius Biotech

06 Jun 2023 Results evaluating safety of HLX-007 in combination with chemotherapy in patients with advanced solid tumours were presented at the 59th Annual Meeting of the American Society of Clinical Oncology
26 May 2023 Results presented in a Shanghai Henlius Biotech media release.
26 May 2023 According to a Shanghai Henlius Biotech media release, results from this study were released as online abstract by 2023 American Society of Clinical Oncology (ASCO) Annual Meeting for the first time.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com